THURSDAY 28th NOVEMBER
SESSION 1: GENOMIC AND SIGNALLING PERSPECTIVES IN CANCER
Using cancer genome data for driver identification
Rosario García-Campelo, Complejo Hospitalario Universitario de A Coruña. – Presentación
New functional classes of tumorigenic drivers
José Tubio, Centro de Investigación CIMUS, Santiago de Compostela. – Presentación
The inflammatory cytokine oncostatin M promotes breast cancer progression
Andrea Abaurrea, Instituto de Investigación Sanitaria Biodonostia, Donostia-San Sebastián – Presentación
Development of adenocarcinoma and sarcomatoid carcinoma after inactivation of Trp53 and Pten in mouse lung
Sara Lázaro Encinas, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas-CIEMAT, Madrid. – Presentación
Study of PTEN and p53 as tumor suppressors: development of animal models for the study of tumor progression in endometrial cancer
Raúl Navaridas Fernández de Bobadilla, Institut de Recerca Biomèdica, Lleida. – Presentación
Study of cell polarity effects on signaling by TFG-B and its role in endometrial carcinogenesis
Anna Ruiz Mitjana, Institut de Recerca Biomèdica, Lleida – Presentación
Optimizing crosstalk between basic and clinical research for improved clinical care. Where we stand and what is missing
Joaquín Arribas, ICREA-Vall d’Hebron Institut d’Oncologia, Barcelona. – Presentación
SESSION 2: TARGETED THERAPIES: CHALLENGES AND PROMISES
Tyrosine kinase receptors & personalized medicine: lung cancer as an example
Noemí Reguart. Hospital Clínic de Barcelona – Presentación
Use of antibody conjugates as a new therapeutic approach
Luis Álvarez Vallina, Instituto de investigación 12 de octubre, Madrid.– Presentación
Activation of cancer associated fibroblasts by oncostatin M contributes to breast cancer progression
Angela M. Araujo, Instituto de Investigación Sanitaria Biodonostia, Donostia-San Sebastián. – Presentación
Deciphering the role of guanine-7 tRNA methylation in prostate cancer progression
Raquel García-Vílchez, Instituto de Biología Molecular y Celular del Cáncer, Salamanca. – Presentación
SESSION 3: NEW THERAPEUTIC APPROACHES: IMMUNOTHERAPIES
Setting up the stage: current immunotherapy avenues
África González, President of the Spanish Society for Immunology. – Presentación
Immunotherapies to overcome immunosuppression: promises and challenges
Jon Zugazagoitia, Hospital Universitario 12 de Octubre, Madrid. – Presentación
Cell-based immunotherapy: CAR-T and other adoptive cell therapies
Sònia Guedan, IDIBAPS – Hospital Clinic de Barcelona. – Presentación
The clinical impact of using complex molecular profiling strategies in routine oncology and pathology practice
Jesús García-Foncillas, Hospital Universitario Fundación Jiménez Díaz, Madrid. – Presentación
Neoantigenicity and TMB in immunotherapy responses
Javier de Castro, Hospital Universitario La Paz, Madrid. – Presentación
ASEICA YOUNG ROUND TABLE. PROFESSIONAL OPPORTUNITIES FOR CANCER RESEARCHERS OUTSIDE ACADEMIA
ASEICA Joven
María M. Caffarel, Instituto de Investigación Sanitaria Biodonostia, Donostia-San Sebastián. – Presentación
Transition from academia to industry, working abroad
José Medina-Echeverz, Bavarian Nordic Research Institute, Munich. – Presentación
FRIDAY 29th NOVEMBER
SESSION 4: CURRENT THERAPEUTIC CHALLENGES AND NEW FRONTIERS IN CANCER
Ras oncoproteins: drugabble or undruggable?
Esther Castellano, Centro de Investigación del Cáncer, Salamanca – Presentación
Cancer cell plasticity during metastasis and therapeutic implications
Antoni Celià-Terrassa, Institut d’Hospital del Mar d’investigacions Mèdiques, Barcelona– Presentación
Activity of chemotherapy drugs in patient-derived xenografts (pdxs) from triple negative breast cancer (tnbc) patients
Rebeca Bernat Gómez, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid. – Presentación
Optimizing hormonotherapy: the model of prostate cancer
David Olmos, CNIO, Madrid. – Presentación
Therapeutic value of cell cycle inhibitors
Javier Cortés, IOB, Institute of Oncology, QuironSalud Group, Madrid & Barcelona Vall d´Hebron Institute of Oncology (VHIO), Barcelona. – Presentación
ASEICA WOMAN SESSION
Effective communication
José Cano, IDC Research España. – Presentación
SESSION 5: LIQUID BIOPSY AND OTHER EMERGING TECHNOLOGIES
When the non-coding codes: identifying novel micropeptides relevant for cancer
María Abad, Hospital Universitari Vall d’Hebron, Barcelona. – Presentación
EACR
European Association for Cancer Research. – Presentación
[…] Presentaciones | II ASEICA EDUCATIONAL SYMPOSIUM 2019 […]